Page 50 - ARNM-3-1

Advances in Radiotherapy
& Nuclear Medicine EZH2 inhibition in ARID1A-deficient TNBC

38. Schade AE, Perurena N, Yang Y, et al. AKT and EZH2 50. He S, Liu Y, Meng L, et al. EZH2 phosphorylation state
inhibitors kill TNBC by hijacking mechanisms of determines its capacity to maintain CD8 T memory
+
S
involution. Nature. 2024;635:755-763. precursors for antitumor immunity. Nat Commun.
doi: 10.1038/s41586-024-08031-6 2017;8(1):2125.
39. Huang R, Wu Y, Zou Z. Combining EZH2 inhibitors with doi: 10.1038/s41467-017-02187-8
other therapies for solid tumors: More choices for better 51. Huang S, Wang Z, Zhou J, et al. EZH2 Inhibitor GSK126
effects. Epigenomics. 2022;14(22):1449-1464. suppresses antitumor immunity by driving production
doi: 10.2217/epi-2022-0320 of myeloid-derived suppressor cells. Cancer Res.
2019;79(8):2009-2020.
40. Hoy SM. Tazemetostat: First approval. Drugs. 2020;80(5):513-521.
doi: 10.1158/0008-5472.Can-18-2395
doi: 10.1007/s40265-020-01288-x
52. Zheng Y, Li S, Tang H, Meng X, Zheng Q. Molecular
41. Von Keudell G, Salles G. The role of tazemetostat in relapsed/ mechanisms of immunotherapy resistance in triple-negative
refractory follicular lymphoma. Ther Adv Hematol. 2021;12. breast cancer. Front Immunol. 2023;14:1153990.
doi: 10.1177/20406207211015882 doi: 10.3389/fimmu.2023.1153990
42. Wang C, Chen X, Liu X, et al. Discovery of precision 53. Luo L, Wang Z, Hu T, et al. Multiomics characteristics and
targeting EZH2 degraders for triple-negative breast cancer. immunotherapeutic potential of EZH2 in pan-cancer. Biosci
Eur J Med Chem. 2022;238:114462. Rep. 2023;43(1).
doi: 10.1016/j.ejmech.2022.114462 doi: 10.1042/bsr2022223054
43. Ma A, Stratikopoulos E, Park KS, et al. Discovery of a 54. Nanda R, Chow LQ, Dees EC, et al. Pembrolizumab in
first-in-class EZH2 selective degrader. Nat Chem Biol. patients with advanced triple-negative breast cancer: Phase Ib
2020;16(2):214-222. KEYNOTE-012 study. J Clin Oncol. 2016;34(21):2460-2467.
doi: 10.1038/s41589-019-0421-4 doi: 10.1200/jco.2015.64.8931
44. Mei H, Wu H, Yang J, et al. Discovery of IHMT-337 as 55. Loi S, Salgado R, Schmid P, et al. Association between
a potent irreversible EZH2 inhibitor targeting CDK4 biomarkers and clinical outcomes of pembrolizumab
transcription for malignancies. Signal Transduct Target Ther. monotherapy in patients with metastatic triple-negative
2023;8(1):18. breast cancer: KEYNOTE-086 exploratory analysis. JCO
doi: 10.1038/s41392-022-01240-3 Precis Oncol. 2023;7:e2200317.
45. Margueron R, Li G, Sarma K, et al. EZH1 and EZH2 maintain doi: 10.1200/po.22.00317
repressive chromatin through different mechanisms. Mol 56. Rosenthal R, Cadieux EL, Salgado R, et al. Neoantigen-
Cell. 2008;32(4):503-518. directed immune escape in lung cancer evolution. Nature.
doi: 10.1016/j.molcel.2008.11.004 2019;567(7749):479-485.
46. Yoo KH, Oh S, Kang K, Hensel T, Robinson GW, doi: 10.1038/s41586-019-1032-7
Hennighausen L. Loss of EZH2 results in precocious 57. Garrido F, Aptsiauri N, Doorduijn EM, Garcia Lora AM, van
mammary gland development and activation of STAT5- Hall T. The urgent need to recover mhc class I in cancers for
dependent genes. Nucleic Acids Res. 2015;43(18):8774-8789. effective immunotherapy. Curr Opin Immunol. 2016;39:44-51.
doi: 10.1093/nar/gkv776 doi: 10.1016/j.coi.2015.12.007
47. Shen X, Liu Y, Hsu YJ, et al. EZH1 mediates methylation on 58. Burr ML, Sparbier CE, Chan KL, et al. An evolutionarily
histone H3 lysine 27 and complements EZH2 in maintaining conserved function of polycomb silences the MHC class I
stem cell identity and executing pluripotency. Mol Cell. antigen presentation pathway and enables immune evasion
2008;32(4):491-502. in cancer. Cancer Cell. 2019;36(4):385-401.e8.
doi: 10.1016/j.molcel.2008.10.016 doi: 10.1016/j.ccell.2019.08.008
48. Zhao E, Maj T, Kryczek I, et al. Cancer mediates effector 59. Bayerl F, Meiser P, Donakonda S, et al. Tumor-derived
T cell dysfunction by targeting micrornas and EZH2 via prostaglandin E2 programs CDC1 dysfunction to impair
glycolysis restriction. Nat Immunol. 2016;17(1):95-103. intratumoral orchestration of anti-cancer T cell responses.
doi: 10.1038/ni.3313 Immunity. 2023;56(6):1341-1358.e11.
49. Guillerey C, Smyth MJ. NK cells and cancer immunoediting. doi: 10.1016/j.immuni.2023.05.011
Curr Top Microbiol Immunol. 2016;395:115-145.
60. Willingham SB, Volkmer JP, Gentles AJ, et al. The CD47-
doi: 10.1007/82_2015_446 signal regulatory protein alpha (SIRPa) interaction is a

Volume 3 Issue 1 (2025) 42 doi: 10.36922/arnm.5132